News articles about PerkinElmer (NYSE:PKI) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. PerkinElmer earned a news impact score of 0.16 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 46.4867583908246 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of research analysts have issued reports on PKI shares. Morgan Stanley boosted their target price on shares of PerkinElmer from $77.00 to $78.00 and gave the company an “overweight” rating in a research note on Friday, November 3rd. Robert W. Baird boosted their target price on shares of PerkinElmer from $75.00 to $78.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Citigroup reissued a “buy” rating and set a $80.00 target price (up from $74.00) on shares of PerkinElmer in a research note on Tuesday, September 26th. Jefferies Group reissued a “hold” rating and set a $70.00 target price on shares of PerkinElmer in a research note on Friday, October 20th. Finally, ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $68.64.
PerkinElmer (PKI) traded up $1.24 during mid-day trading on Friday, hitting $72.13. 1,170,000 shares of the company’s stock were exchanged, compared to its average volume of 575,011. PerkinElmer has a one year low of $50.59 and a one year high of $74.11. The company has a market cap of $7,950.53, a P/E ratio of 25.95, a price-to-earnings-growth ratio of 2.16 and a beta of 0.77. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.59 and a quick ratio of 2.09.
In other PerkinElmer news, Director Peter Barrett sold 7,071 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $71.07, for a total transaction of $502,535.97. Following the sale, the director now directly owns 26,271 shares in the company, valued at approximately $1,867,079.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Frank Anders Wilson sold 37,535 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $70.14, for a total transaction of $2,632,704.90. The disclosure for this sale can be found here. Insiders have sold a total of 73,656 shares of company stock worth $5,201,957 over the last 90 days. 2.20% of the stock is owned by insiders.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.